Integrace Health
July 2026
Announced Date: July 2026
Value: Undisclosed
o3 Capital acted as the Exclusive Financial Advisor to Integrace on its acquisition by Warburg Pincus
We are pleased to announce that our client, Integrace has been acquired by Warburg Pincus, as part of its investment in a private equity-backed domestic formulations platform. The platform will be led by Rehan Khan, former CEO of MSD India.
The transaction also reinforces o3 Capital’s credentials in the Indian Life Sciences and Healthcare sector, where the firm has advised on 12 transactions over the past two years.
Speaking on the transaction, Shiraz Bugwadia, Managing Partner at o3 Capital, said: “We are proud to have advised on the Integrace transaction — a marquee deal that reflects exactly the kind of high-conviction, therapy-focused M&A that India's domestic pharmaceutical sector is primed for. With its differentiated portfolio and deep prescriber relationships, Integrace offers a strong foundation for a scaled, specialist-led platform in high-growth therapies. It is well positioned for its next phase of growth, and we look forward to seeing the platform scale.”
Satish Chander, Co-Managing Partner, at True North, said: “We are proud to have partnered with the Integrace team as they built it into a strong quality healthcare company that established a deep and respectable position amongst specialists through its science-based marketing practices. We wish Rehan, Warburg Pincus and the entire team continued success in the next phase of growth. We would also like to thank o3 Capital team who were instrumental in bringing this transaction to a seamless and timely close.”
Himanshu Nema, Managing Director at Warburg Pincus, said: “Integrace has built an exceptional foundation with a differentiated portfolio in orthopaedics and gynaecology, a strong position in the high-growth therapeutics segments and trusted relationships with specialists. This acquisition reflects our conviction in therapy-focused, brand-led platforms and our ambition to build a scaled, market-leading pharmaceuticals business in India. We are excited to partner with Rehan and the team on this journey.”
Integrace is one of India's leading orthopaedics and gynaecology-focused domestic formulations companies. The Company has a portfolio of 20+ products catering to pain management, pregnancy and women’s health, with 5 power brands ranking among the top 3 in their respective markets. Supported by science-backed marketing, the Company has cultivated a high-quality specialist coverage base of over 45,000 healthcare professionals across orthopaedics and gynaecologists.
Warburg Pincus is one of the oldest private equity firms in the world, with more than $105 billion in assets under management, and more than 225 companies in its active portfolio, diversified across stages, sectors, and geographies. Warburg Pincus has invested in more than 1,100 companies across its private equity, real estate, and capital solutions strategies.
About o3 Capital
o3 Capital is a leading mid-market investment bank focused on delivering differentiated outcomes across private equity, M&A, structured finance, and strategic advisory. With deep sector expertise and long-standing client relationships, o3 Capital partners with entrepreneurs and institutions to drive transformational growth and value creation.
We are pleased to announce that our client, Integrace has been acquired by Warburg Pincus, as part of its investment in a private equity-backed domestic formulations platform. The platform will be led by Rehan Khan, former CEO of MSD India.
The transaction also reinforces o3 Capital’s credentials in the Indian Life Sciences and Healthcare sector, where the firm has advised on 12 transactions over the past two years.
Speaking on the transaction, Shiraz Bugwadia, Managing Partner at o3 Capital, said: “We are proud to have advised on the Integrace transaction — a marquee deal that reflects exactly the kind of high-conviction, therapy-focused M&A that India's domestic pharmaceutical sector is primed for. With its differentiated portfolio and deep prescriber relationships, Integrace offers a strong foundation for a scaled, specialist-led platform in high-growth therapies. It is well positioned for its next phase of growth, and we look forward to seeing the platform scale.”
Satish Chander, Co-Managing Partner, at True North, said: “We are proud to have partnered with the Integrace team as they built it into a strong quality healthcare company that established a deep and respectable position amongst specialists through its science-based marketing practices. We wish Rehan, Warburg Pincus and the entire team continued success in the next phase of growth. We would also like to thank o3 Capital team who were instrumental in bringing this transaction to a seamless and timely close.”
Himanshu Nema, Managing Director at Warburg Pincus, said: “Integrace has built an exceptional foundation with a differentiated portfolio in orthopaedics and gynaecology, a strong position in the high-growth therapeutics segments and trusted relationships with specialists. This acquisition reflects our conviction in therapy-focused, brand-led platforms and our ambition to build a scaled, market-leading pharmaceuticals business in India. We are excited to partner with Rehan and the team on this journey.”
Integrace is one of India's leading orthopaedics and gynaecology-focused domestic formulations companies. The Company has a portfolio of 20+ products catering to pain management, pregnancy and women’s health, with 5 power brands ranking among the top 3 in their respective markets. Supported by science-backed marketing, the Company has cultivated a high-quality specialist coverage base of over 45,000 healthcare professionals across orthopaedics and gynaecologists.
Warburg Pincus is one of the oldest private equity firms in the world, with more than $105 billion in assets under management, and more than 225 companies in its active portfolio, diversified across stages, sectors, and geographies. Warburg Pincus has invested in more than 1,100 companies across its private equity, real estate, and capital solutions strategies.
About o3 Capital
o3 Capital is a leading mid-market investment bank focused on delivering differentiated outcomes across private equity, M&A, structured finance, and strategic advisory. With deep sector expertise and long-standing client relationships, o3 Capital partners with entrepreneurs and institutions to drive transformational growth and value creation.